Contribution of functional KIR3DL1 to ankylosing spondylitis.
Increasing evidence points to a role for killer immunoglobulin-like receptors (KIRs) in the development of autoimmune diseases. In particular, a positive association of KIR3DS1 (activating receptor) and a negative association of KIR3DL1 (inhibitory receptor) alleles with ankylosing spondylitis (AS) have been reported by several groups. However, none of the studies analyzed these associations in the context of functionality of polymorphic KIR3DL1. To better understand how the KIR3DL1/3DS1 genes determine susceptibility to AS, we analyzed the frequencies of alleles and genotypes encoding functional (KIR3DL1*F) and non-functional (KIR3DL1*004) receptors. We genotyped 83 AS patients and 107 human leukocyte antigen (HLA)-B27-positive healthy controls from the Russian Caucasian population using a two-stage sequence-specific primer PCR, which distinguishes KIR3DS1, KIR3DL1*F and KIR3DL1*004 alleles. For the patients carrying two functional KIR3DL1 alleles, those alleles were additionally genotyped to identify KIR3DL1*005 and KIR3DL1*007 alleles, which are functional but are expressed at low levels. KIR3DL1 was negatively associated with AS at the expense of KIR3DL1*F but not of KIR3DL1*004. This finding indicates that the inhibitory KIR3DL1 receptor protects against the development of AS and is not simply a passive counterpart of the segregating KIR3DS1 allele encoding the activating receptor. However, analysis of genotype frequencies indicates that the presence of KIR3DS1 is a more important factor for AS susceptibility than the absence of KIR3DL1*F. The activation of either natural killer (NK) or T cells via the KIR3DS1 receptor can be one of the critical events in AS development, while the presence of the functional KIR3DL1 receptor has a protective effect. Nevertheless, even individuals with a genotype that carried two inhibitory KIR3DL1 alleles expressed at high levels could develop AS.
Zvyagin
Ivan V
IV
Shemiakin-Ovchinnikov Institute of Bioorganic Chemistry, RAS, Moscow, Russia.
Mamedov
Ilgar Z
IZ
Britanova
Olga V
OV
Staroverov
Dmitriy B
DB
Nasonov
Evgeni L
EL
Bochkova
Anna G
AG
Chkalina
Anna V
AV
Kotlobay
Alexei A
AA
Korostin
Dmitriy O
DO
Rebrikov
Denis V
DV
Lukyanov
Sergey
S
Lebedev
Yuri B
YB
Chudakov
Dmitriy M
DM
D000328:Adult; D000483:Alleles; D016022:Case-Control Studies; D005787:Gene Frequency / Q000235:genetics; D006579:Heterozygote; D006801:Humans; D008875:Middle Aged; D054341:Receptors, KIR3DL1 / Q000235:genetics*; D054349:Receptors, KIR3DS1 / Q000235:genetics; D012426:Russia; D013030:Spain; D013167:Spondylitis, Ankylosing / Q000235:genetics*; D044465:White People / Q000235:genetics
C515083:KIR3DL1 protein, human; D054341:Receptors, KIR3DL1; D054349:Receptors, KIR3DS1
Rheumatology (Oxford). 2002 Aug;41(8):857-68
12154202
PLoS Genet. 2008 Nov;4(11):e1000254
19008943
J Immunol. 2004 Dec 15;173(12):7223-9
15585844
N Engl J Med. 1973 Apr 5;288(14):704-6
4688372
AIDS Res Hum Retroviruses. 2007 Mar;23(3):451-5
17411378
Arthritis Rheum. 1984 Apr;27(4):361-8
6231933
Immunity. 1997 Dec;7(6):753-63
9430221
Hum Immunol. 2008 Jul;69(7):437-42
18638658
Proc Natl Acad Sci U S A. 1996 Feb 20;93(4):1453-7
8643653
Ann Rheum Dis. 2009 Apr;68(4):595-8
19019897
Annu Rev Immunol. 2002;20:217-51
11861603
Semin Immunol. 2008 Dec;20(6):343-52
18635379
Nat Genet. 2002 Aug;31(4):429-34
12134147
Best Pract Res Clin Rheumatol. 2006 Jun;20(3):571-91
16777583
Zhonghua Yi Xue Za Zhi. 2009 Jan 13;89(2):91-5
19489269
Hum Immunol. 2006 Jul;67(7):521-6
16829306
Ann Rheum Dis. 2010 Apr;69(4):733-6
19433412
J Exp Med. 2006 Mar 20;203(3):633-45
16533882
Mol Immunol. 2005 Feb;42(4):459-62
15607799
Nat Genet. 2007 Nov;39(11):1329-37
17952073
Hum Mol Genet. 2009 Nov 1;18(21):4204-12
19692350
Nature. 1998 Feb 12;391(6668):703-7
9490415
J Exp Med. 1995 Mar 1;181(3):1133-44
7532677
Curr Opin Rheumatol. 2009 Jul;21(4):318-23
19496308
Ann Neurol. 2009 Jun;65(6):658-66
19630074
J Immunol. 2003 Dec 15;171(12):6640-9
14662867
Lancet. 1973 Apr 28;1(7809):904-7
4123836
Eur J Immunol. 2005 Jan;35(1):16-24
15580659
Genome Res. 2005 Jan;15(1):25-35
15632087
Arthritis Rheum. 2005 Nov;52(11):3586-95
16255049
J Clin Immunol. 2008 Jul;28(4):343-9
18297378
J Immunol. 2008 Mar 1;180(5):2767-71
18292496
J Exp Med. 2007 Nov 26;204(12):3027-36
18025129
Proc Natl Acad Sci U S A. 1997 Sep 16;94(19):10285-8
9294202
Eur J Immunol. 2007 Mar;37(3):780-7
17301953
Rheumatology (Oxford). 2008 Feb;47(2):132-7
18037607
J Immunol. 2009 Jan 1;182(1):92-101
19109139
Int J Immunogenet. 2008 Feb;35(1):1-8
18093180
Curr Opin Rheumatol. 2006 Jul;18(4):332-41
16763451
J Exp Med. 1994 Aug 1;180(2):537-43
8046332
Rheumatology (Oxford). 2007 May;46(5):763-71
17259653
Adv Exp Med Biol. 2009;649:286-99
19731638
J Immunol. 2007 Aug 1;179(3):1625-33
17641029
J Immunol. 2001 Mar 1;166(5):2992-3001
11207248
Nat Rev Immunol. 2005 Mar;5(3):201-14
15719024
Arthritis Res Ther. 2006;8(4):R101
16805919
Arthritis Rheum. 2009 May;60(5):1317-23
19404951
Eur J Immunol. 2005 Jul;35(7):2191-9
15940669
J Immunol. 2004 Oct 1;173(7):4273-6
15383555
Curr Mol Med. 2004 Feb;4(1):13-20
15011955
J Invest Dermatol. 2005 Oct;125(4):721-30
16185272
Nat Genet. 2007 Jun;39(6):733-40
17496894
Methods Mol Biol. 2008;415:49-64
18370147
J Clin Pathol. 1973 May;26(5):387
4714966